Medications like Ozempic and Wegovy, which contain semaglutide — a GLP‑1 receptor agonist that helps regulate blood sugar, appetite and body weight — have become household names and important pillars in obesity management for the medical profession.
Research has shown GLP-1 medications reduce body weight by an average of 15 per cent when used weekly for 68 weeks and combined with lifestyle interventions. This is because semaglutide acts on the brain to increase the feeling of fullness and to decrease appetite.